BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35765698)

  • 1. Nordic treatment guidelines for rare epileptic conditions: A literature review.
    Vyas K; Luedke H; Ruban-Fell B
    Brain Behav; 2022 Jul; 12(7):e2622. PubMed ID: 35765698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Guidelines for Rare, Early-Onset, Treatment-Resistant Epileptic Conditions: A Literature Review on Dravet Syndrome, Lennox-Gastaut Syndrome and CDKL5 Deficiency Disorder.
    Chin RF; Mingorance A; Ruban-Fell B; Newell I; Evans J; Vyas K; Nortvedt C; Amin S
    Front Neurol; 2021; 12():734612. PubMed ID: 34759881
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment guidelines for rare, early-onset conditions associated with epileptic seizures: a literature review on Rett syndrome and tuberous sclerosis complex.
    Amin S; Ruban-Fell B; Newell I; Evans J; Vyas K; Nortvedt C; Chin RF
    Orphanet J Rare Dis; 2024 Feb; 19(1):89. PubMed ID: 38409029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
    Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F
    CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient and Caregiver Health State Utilities in Lennox-Gastaut Syndrome and Dravet Syndrome.
    Lo SH; Lloyd A; Marshall J; Vyas K
    Clin Ther; 2021 Nov; 43(11):1861-1876.e16. PubMed ID: 34774333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A quantitative cross-sectional study of the burden of caring for patients with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex-associated epilepsy in Japan.
    LoPresti M; Igarashi A; Sonohara Y; Bowditch S
    Epilepsy Behav; 2024 May; 154():109741. PubMed ID: 38555725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome.
    Lattanzi S; Zaccara G; Russo E; La Neve A; Lodi MAM; Striano P
    Expert Rev Neurother; 2021 Jan; 21(1):99-110. PubMed ID: 33026899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
    Silvinato A; Floriano I; Bernardo WM
    Rev Assoc Med Bras (1992); 2022; 68(10):1345-1357. PubMed ID: 36417631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of seizure frequency on quality of life in patients with Lennox-Gastaut syndrome or Dravet syndrome.
    Auvin S; Damera V; Martin M; Holland R; Simontacchi K; Saich A
    Epilepsy Behav; 2021 Oct; 123():108239. PubMed ID: 34375802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
    Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
    Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
    Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
    Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Providing quality care for people with CDKL5 deficiency disorder: A European expert panel opinion on the patient journey.
    Amin S; Møller RS; Aledo-Serrano A; Arzimanoglou A; Bager P; Jóźwiak S; Kluger GJ; López-Cabeza S; Nabbout R; Partridge CA; Schubert-Bast S; Specchio N; Kälviäinen R
    Epilepsia Open; 2024 Jun; 9(3):832-849. PubMed ID: 38450883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol.
    Villanueva V; Carreño-Martínez M; Gil Nagel-Rein A; López-González FJ
    Rev Neurol; 2021 Apr; 72(S01):S1-S10. PubMed ID: 33908026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and future pharmacotherapy options for drug-resistant epilepsy.
    Elkommos S; Mula M
    Expert Opin Pharmacother; 2022 Dec; 23(18):2023-2034. PubMed ID: 36154780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea.
    Koo CM; Kim SH; Lee JS; Park BJ; Lee HK; Kim HD; Kang HC
    J Korean Med Sci; 2020 Dec; 35(50):e427. PubMed ID: 33372424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain.
    García-Peñas JJ; Gil Nagel-Rein A; Sánchez-Carpintero R; Villanueva-Haba V
    Rev Neurol; 2021 Sep; 73(S01):S1-S8. PubMed ID: 34486101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
    Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
    Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Few individuals with Lennox-Gastaut syndrome have autism spectrum disorder: a comparison with Dravet syndrome.
    He N; Li BM; Li ZX; Wang J; Liu XR; Meng H; Tang B; Bian WJ; Shi YW; Liao WP
    J Neurodev Disord; 2018 Mar; 10(1):10. PubMed ID: 29558884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The severe epilepsy syndromes of infancy: A population-based study.
    Howell KB; Freeman JL; Mackay MT; Fahey MC; Archer J; Berkovic SF; Chan E; Dabscheck G; Eggers S; Hayman M; Holberton J; Hunt RW; Jacobs SE; Kornberg AJ; Leventer RJ; Mandelstam S; McMahon JM; Mefford HC; Panetta J; Riseley J; Rodriguez-Casero V; Ryan MM; Schneider AL; Smith LJ; Stark Z; Wong F; Yiu EM; Scheffer IE; Harvey AS
    Epilepsia; 2021 Feb; 62(2):358-370. PubMed ID: 33475165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A framework for understanding quality of life domains in individuals with the CDKL5 deficiency disorder.
    Tangarorang J; Leonard H; Epstein A; Downs J
    Am J Med Genet A; 2019 Feb; 179(2):249-256. PubMed ID: 30561084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.